A Phase 1/2 interventional study of P03277 and Placebo in Healthy Volunteers and Brain Lesion, sponsored by Guerbet. Completed at 1 site in Belgium. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-14.
Sponsored by Guerbet · Phase 1/2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study was to evaluate the safety (clinical and biological) and pharmacokinetics (plasma and urine) profile of P03277 following single administration at ascending dose levels in healthy subjects.
This single-center, single ascending dose, phase I/IIa study was divided into 2 parts, involving both healthy subjects and patients with brain lesions:
In Part I, the following 6 dosing groups were investigated:
Healthy subjects were included and were then administered with P03277 or placebo and were to undergo MRI examination according to the randomization scheme.
In Part II, the following 4 doses groups were investigated:
Patients with brain lesions were included and were then administered with P03277 and underwent MRI examination.
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In each dose group (0.025, 0.05, 0.075, 0.1, 0.2 and 0.3 mmol/kg), 9 healthy subjects were to be included: 6 subjects received P03277 and 3 subjects received placebo in one single intravenous administration.
Drug: P03277 · Drug: Placebo
In each dose group (0.05, 0.075, 0.1 and 0.2 mmol/kg), all 3 patients received one single intravenous administration of P03277.
Drug: P03277
Part I: P03277 was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: P03277 was administered intravenously with a flow rate of 2 mL/s.
Also known as: Gadopiclenol
Part I: Placebo was administered intravenously with a flow rate ranging from 0.5 to 2 mL/s. Part II: Placebo was administered intravenously with a flow rate of 2 mL/s.
Also known as: NaCl 0.9%
Pharmacokinetic (PK) Parameter Cmax
Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.
Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
PK Parameter T1/2
T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.
Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
PK Parameter Cl
Cl = total clearance. Blood samples were taken to assess the P03277 concentration.
Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
PK Parameter Vd
Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.
Time frame: From baseline (30 minutes before injection) to 24 hours post-injection
| Milestone | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 3 | 3 | 3 | 3 |
| Completed | 6 | 6 | 6 | 6 | 6 | 6 | 18 | 3 | 3 | 3 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cmax = maximum concentration measured. Blood samples were taken to assess the P03277 concentration.
| µg/mL | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part II (Phase IIA) 0.05 mmol/kg | Part II (Phase IIA) 0.075 mmol/kg | Part II (Phase IIA) 0.1 mmol/kg | Part II (Phase IIA) 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacokinetic (PK) Parameter Cmax | 248.7 ± 54.5 | 524.5 ± 69.9 | 698.7 ± 378.9 | 992.0 ± 233.1 | 2097.6 ± 572.3 | 3916.4 ± 1114.8 | 370.8 ± 117.6 | 618.2 ± 439.7 | 701.6 ± 48.5 | 1434.9 ± 651.5 |
T1/2 = terminal elimination half-life of the compound. Blood samples were taken to assess the P03277 concentration.
| hours | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part II (Phase IIA) 0.05 mmol/kg | Part II (Phase IIA) 0.075 mmol/kg | Part II (Phase IIA) 0.1 mmol/kg | Part II (Phase IIA) 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| PK Parameter T1/2 | 1.65 ± 0.43 | 1.50 ± 0.22 | 1.58 ± 0.30 | 1.73 ± 0.26 | 1.82 ± 0.35 | 2.09 ± 0.15 | 1.90 ± 0.04 | 2.04 ± 0.06 | 1.79 ± 0.17 | 1.94 ± 0.06 |
Cl = total clearance. Blood samples were taken to assess the P03277 concentration.
| mL/min | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part II (Phase IIA) 0.05 mmol/kg | Part II (Phase IIA) 0.075 mmol/kg | Part II (Phase IIA) 0.1 mmol/kg | Part II (Phase IIA) 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| PK Parameter Cl | 91.7 ± 8.5 | 100.1 ± 9.5 | 106.4 ± 20.7 | 96.1 ± 11.8 | 101.3 ± 10.9 | 102.2 ± 19.0 | 105.3 ± 13.5 | 106.5 ± 15.7 | 108.6 ± 5 | 109.9 ± 18.2 |
Vd = volume of distribution. Blood samples were taken to assess the P03277 concentration.
| mL | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part II (Phase IIA) 0.05 mmol/kg | Part II (Phase IIA) 0.075 mmol/kg | Part II (Phase IIA) 0.1 mmol/kg | Part II (Phase IIA) 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|
| PK Parameter Vd | 13203 ± 4122 | 12945 ± 1692 | 14312 ± 2742 | 14351 ± 2645 | 15922 ± 3224 | 18487 ± 3575 | 17320 ± 1942 | 18796 ± 2478 | 16823 ± 804 | 18355 ± 2522 |
Collected over For Part I: adverse events were collected from subjects' enrollment until 7 days after the product (P03277 or placebo) administration. For Part II: adverse events were collected from patients' enrollment until 1 day after P03277 administration.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part I (Phase I) P03277 0.025 mmol/kg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part I (Phase I) P03277 0.05 mmol/kg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part I (Phase I) P03277 0.075 mmol/kg | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| Part I (Phase I) P03277 0.1 mmol/kg | 0/6 (0%) | 0/6 (0%) | 4/6 (66.7%) |
| Part I (Phase I) P03277 0.2 mmol/kg | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| Part I (Phase I) P03277 0.3 mmol/kg | 0/6 (0%) | 0/6 (0%) | 3/6 (50%) |
| Part I (Phase I) Placebo | 0/18 (0%) | 0/18 (0%) | 11/18 (61.1%) |
| Part II (Phase IIA) P03277 0.05 mmol/kg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Part II (Phase IIA) P03277 0.075 mmol/kg | 0/3 (0%) | 1/3 (33.3%) | 1/3 (33.3%) |
| Part II (Phase IIA) P03277 0.1 mmol/kg | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| Part II (Phase IIA) P03277 0.2 mmol/kg | 0/3 (0%) | 0/3 (0%) | 2/3 (66.7%) |
| Event | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abortion inducedSurgical and medical procedures | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/18 | 0/3 | 1/3 | 0/3 | 0/3 |
| Event | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Catheter site painGeneral disorders | 0/6 | 1/6 | 0/6 | 0/6 | 3/6 | 0/6 | 1/18 | 0/3 | 0/3 | 0/3 | 1/3 |
| Injection site painGeneral disorders | 1/6 | 0/6 | 0/6 | 0/6 | 2/6 | 1/6 | 3/18 | 0/3 | 0/3 | 0/3 | 0/3 |
| HeadacheNervous system disorders | 0/6 | 1/6 | 0/6 | 1/6 | 1/6 | 2/6 | 5/18 | 0/3 | 0/3 | 0/3 | 1/3 |
| Influenza like illnessGeneral disorders | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/18 | 0/3 | 0/3 | 1/3 | 0/3 |
| Decreased appetiteMetabolism and nutrition disorders | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/18 | 1/3 | 0/3 | 0/3 | 0/3 |
| PregnancyPregnancy, puerperium and perinatal conditions | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/18 | 0/3 | 1/3 | 0/3 | 0/3 |
| Injection site oedemaGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 1/6 | 0/6 | 1/18 | 0/3 | 0/3 | 0/3 | 0/3 |
| FatigueGeneral disorders | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 1/18 | 0/3 | 0/3 | 0/3 | 0/3 |
| Catheter site dermatitisGeneral disorders | 0/6 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/18 | 0/3 | 0/3 | 0/3 | 0/3 |
| Injection site coldnessGeneral disorders | 0/6 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/18 | 0/3 | 0/3 | 0/3 | 0/3 |
All patients who received one injection of product (placebo or P03277 for Part I, P03277 for Part II).
| Age, Continuous(years) | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 26.0 (22 to 30) | 25.5 (21 to 37) | 27.5 (23 to 40) | 25.5 (23 to 41) | 23.0 (18 to 36) | 33.5 (23 to 42) | 26.5 (19 to 43) | 40.0 (37 to 50) | 56.0 (25 to 57) | 56.0 (53 to 61) | 53.0 (50 to 58) | 28.0 (18 to 61) |
| Sex: Female, Male(Participants) | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 3 | 4 | 3 | 3 | 3 | 3 | 8 | 1 | 2 | 1 | 1 | 32 |
| Male | 3 | 2 | 3 | 3 | 3 | 3 | 10 | 2 | 1 | 2 | 2 | 34 |
| Weight(kg) | Part I (Phase I) P03277 0.025 mmol/kg | Part I (Phase I) P03277 0.05 mmol/kg | Part I (Phase I) P03277 0.075 mmol/kg | Part I (Phase I) P03277 0.1 mmol/kg | Part I (Phase I) P03277 0.2 mmol/kg | Part I (Phase I) P03277 0.3 mmol/kg | Part I (Phase I) Placebo | Part II (Phase IIA) P03277 0.05 mmol/kg | Part II (Phase IIA) P03277 0.075 mmol/kg | Part II (Phase IIA) P03277 0.1 mmol/kg | Part II (Phase IIA) P03277 0.2 mmol/kg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Median | 81.65 (52.2 to 87.4) | 71.60 (54.0 to 83.6) | 65.00 (56.4 to 93.0) | 72.50 (62.0 to 99.2) | 69.30 (68.2 to 87.6) | 72.50 (61.6 to 88.6) | 67.90 (56.8 to 89.4) | 87.20 (85.8 to 89.0) | 80.40 (71.2 to 87.4) | 87.20 (82.4 to 102.8) | 85.80 (79.4 to 101.6) | 72.85 (52.2 to 102.8) |
Plan to share: No
Ran from Nov 2013 to primary completion in Apr 2015, 16 months.
Results were first posted in Jul 2019, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadopiclenol